ADDED
Reverse Stock Split Unless otherwise indicated, all share amounts and per share amounts have been adjusted retroactively in this Annual Report on Form 10-K to give effect to the 1-for-14 reverse stock split of our common stock effected on March 13, 2026.
These risks include, but are not limited to, the following: We will need to obtain substantial additional capital in the future to finance our operations and complete the development of any current or future product candidates.
If we fail to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
The recently implemented reverse stock split of our common stock may not achieve the intended benefits and could have a materially adverse effect on the market price of our common stock.
We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
In addition, certain of our research and development and manufacturing activities take place in China through WuXi Biologics (Hong Kong) Limited, or WuXi Biologics.
Availability of Other Information About Xilio Therapeutics, Inc.
Investors and others should note that we communicate with our investors and the public using our company website (www.xiliotx.com), including but not limited to investor presentations and scientific presentations, filings with the U.S.
Securities and Exchange Commission, press releases, public conference calls and webcasts.
The information that we post on these channels and websites could be deemed to be material information.
REMOVED
Hoffmann-La Roche Ltd; our expectations regarding milestones, option-related fees and other contingent payments under our collaboration agreement with AbbVie and our license agreement with Gilead; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and the impact of general economic conditions, including inflation.
These risks include, but are not limited to, the following: Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
If we are unable to raise sufficient additional capital in the near term, we will need to implement additional cost reduction strategies, which could include delaying, limiting, reducing or eliminating both internal and external costs related to our operations and research and development programs.
We face risk related to our reliance on our current and any future third-party contract development and manufacturing organizations, or CDMOs.
For example, the CDMO on which we rely may not continue to meet regulatory requirements, may have limited capacity and may experience interruptions in supply, any of which could adversely affect our development and commercialization plans for our product candidates.
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
If in the future we fail to comply with the continued listing requirements of The Nasdaq Stock Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
Business Overview We are a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments.
We are leveraging our proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including masked antibodies, bispecifics, cytokines and immune cell engagers.
Current I-O therapies have curative potential for patients with cancer.